Sustained low-dose growth hormone therapy optimizes bioactive insulin-like growth factor-I level and may enhance CD4 T-cell number in HIV infection

Journal of Medical Virology

Volumn 82, Issue 2, 2010, Pages 197-205

  Andersen, Ove ^a   Hansen, Birgitte Rønde ^a   Troensegaard, William ^a   Flyvbjerg, Allan ^b   Madsbad, Sten ^c   Ørskov, Hans ^b   Nielsen, Jens Ole ^a   Iversen, Johan ^a   Haugaard, Steen B ^a,c  

^a HVIDOVRE HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c Mental Health Center Glostrup   (Denmark)

Author keywords

Antiretroviral therapy; Free IGF I; Immune response; T cell restoration

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; GROWTH HORMONE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; NELFINAVIR; ORAL ANTIDIABETIC AGENT; RECOMBINANT GROWTH HORMONE; RITONAVIR; SAQUINAVIR; SOMATOMEDIN C; STAVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CELLULAR IMMUNITY; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG SAFETY; FLUID RETENTION; GLUCOSE BLOOD LEVEL; GROWTH HORMONE RELEASE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HORMONAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTATE BLOOD LEVEL; LOW DRUG DOSE; MALE; PILOT STUDY; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; TREATMENT OUTCOME;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 74549185686     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21625     Document Type: Article

References (32)

1. Andersen O, Haugaard SB, Flyvbjerg A, Andersen UB, Orskov H, Madsbad S, Nielsen JO, Iversen J. 2004a. Low-dose growth hormone and human immunodeficiency virus-associated lipodystrophy syndrome: A pilot study. Eur J Clin Invest 34:561-568.
2. Andersen O, Haugaard SB, Hansen BR, Orskov H, Andersen UB, Madsbad S, Iversen J, Flyvbjerg A. 2004b. Different growth hormone sensitivity of target tissues and growth hormone response to glucose in HIV-infected patients with and without lipodystrophy. Scand J Infect Dis 36:832-839.
3. Chokkalingam AP, Pollak M, Fillmore CM, Gao YT, Stanczyk FZ, Deng J, Sesterhenn IA, Mostofi FK, Fears TR, Madigan MP, Ziegler RG, Fraumeni JF, Jr., Hsing AW. 2001. Insulin-like growth factors and prostate cancer: A population-based case-control study in China. Cancer Epidemiol Biomarkers Prev 10:421-427.
4. Clark R. 1997. The somatogenic hormones and insulin-like growth factor-1: Stimulators of lymphopoiesis and immune function. Endocr Rev 18:157-179.
5. Clark RG, Mortensen DL, Carlsson LM, Carlsson B, Carmignac D, Robinson IC. 1996. The obese growth hormone (GH)-deficient dwarf rat: Body fat responses to patterned delivery of GH and insulin-like growth factor-I. Endocrinology 137:1904-1912.
6. D'Amico S, Shi J, Sekhar RV, Jahoor F, Ellis KJ, Rehman K, Willis J, Maldonado M, Balasubramanyam A. 2006. Physiologic growth hormone replacement improves fasting lipid kinetics in patients with HIV lipodystrophy syndrome. Am J Clin Nutr 84:204-211.
7. Engelson ES, GlesbyMJ, Mendez D, Albu JB,Wang J, Heymsfield SB, Kotler DP. 2002. Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J Acquir Immune Defic Syndr 30:379-391.
8. Frystyk J, Skjaerbaek C, Dinesen B, Orskov H. 1994. Free insulin-like growth factors (IGF-I and IGF-II) in human serum. FEBS Lett 348:185-191.
9. Frystyk J, Dinesen B, Orskov H. 1995. Non-competitive time-resolved immunofluorometric assays for determination of human insulin-like growth factor I and II. Growth Regul 5:169-176.
10. Ghigo E, Aimaretti G, Maccario M, Fanciulli G, Arvat E, Minuto F, Giordano G, Delitala G, Camanni F. 1999. Dose-response study of GH effects on circulating IGF-I and IGFBP-3 levels in healthy young men and women. Am J Physiol 276:E1009-E1013.
11. Hansen BR, Haugaard SB, Andersen O. 2005. The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients. ClinicalTrials.gov ClinicalTrials.gov Identifier: NCT00119769. 2-2-0005. 2-2-2005.
12. Haugaard SB, Andersen O, Hansen BR, Orskov H, Andersen UB, Madsbad S, Iversen J, Flyvbjerg A. 2004. Insulin-like growth factors, insulin-like growth factor-binding proteins, insulin-like growth factor-binding protein-3 protease, and growth hormone-binding protein in lipodystrophic human immunodeficiency virusinfected patients. Metabolism 53:1565-1573.
13. Haugaard SB, Andersen O, Flyvbjerg A, Orskov H, Madsbad S, Iversen J. 2006. Growth factors, glucose and insulin kinetics after low dose growth hormone therapy in HIV-lipodystrophy. J Infect 52:389-398.
14. Heijligenberg R, Sauerwein HP, Brabant G, Endert E, Hommes MJ, Romijn JA. 1996. Circadian growth hormone secretion in asymptomatic human immune deficiency virus infection and acquired immunodeficiency syndrome. J Clin Endocrinol Metab 81:4028-4032.
15. Herasimtschuk AA, Westrop SJ, Moyle GJ, Downey JS, Imami N. 2008. Effects of recombinant human growth hormone on HIV-1-specific T-cell responses, thymic output and proviral DNA in patients on HAART: 48-week follow-up. J Immune Based Ther Vaccines 6:7.
16. Hunt PW, Deeks SG, Rodriguez B, Valdez H, Shade SB, Abrams DI, Kitahata MM, Krone M, Neilands TB, Brand RJ, Lederman MM, Martin JN. 2003. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 17:1907-1915.
17. Jorgensen JO, Moller N, Lauritzen T, Alberti KG, Orskov H, Christiansen JS. 1990. Evening versus morning injections of growth hormone (GH) in GH-deficient patients: Effects on 24-hour patterns of circulating hormones and metabolites. J Clin Endocrinol Metab 70:207-214.
18. Kolb H, Mandrup-Poulsen T. 2005. An immune origin of type 2 diabetes? Diabetologia 48:1038-1050.
19. Kotler DP, Muurahainen N, Grunfeld C, Wanke C, Thompson M, Saag M, Bock D, Simons G, Gertner JM. 2004. Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr 35:239-252.
20. Koutkia P, Canavan B, Breu J, Torriani M, Kissko J, Grinspoon S. 2004a. Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: A randomized controlled trial. JAMA 292:210-218.
21. Koutkia P, Meininger G, Canavan B, Breu J, Grinspoon S. 2004b. Metabolic regulation of growth hormone by free fatty acids, somatostatin, and ghrelin in HIV-lipodystrophy. Am J Physiol Endocrinol Metab 286:E296-E303.
22. LeRoith D, Yanowski J, Kaldjian EP, Jaffe ES, LeRoith T, Purdue K, Cooper BD, Pyle R, Adler W. 1996. The effects of growth hormone and insulin-like growth factor I on the immune system of aged female monkeys. Endocrinology 137:1071-1079.
23. Lo JC, Mulligan K, Noor MA, Schwarz JM, Halvorsen RA, Grunfeld C, Schambelan M. 2001. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 86:3480-3487.
24. Lo JC, Mulligan K, Noor MA, Lee GA, Schwarz JM, Grunfeld C, Schambelan M. 2004. The effects of low-dose growth hormone in HIV-infected men with fat accumulation: A pilot study. Clin Infect Dis 39:732-735.
25. Lo J, You SM, CanavanB, Liebau J, Beltrani G, Koutkia P, Hemphill L, Lee H, Grinspoon S. 2008. Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: A randomized controlled trial. JAMA 300:509-519.
26. Lohse N, Obel N, Kronborg G, Laursen A, Pedersen C, Larsen CS, Kvinesdal B, Sorensen HT, Gerstoft J. 2005.Declining risk of tripleclass antiretroviral drug failure in Danish HIV-infected individuals. AIDS 19:815-822.
27. Lohse N, Jorgensen LB, Kronborg G, Moller A, Kvinesdal B, Sorensen HT, Obel N, Gerstoft J. 2007. Genotypic drug resistance and longterm mortality in patients with triple-class antiretroviral drug failure. Antivir Ther 12:909-917.
28. Napolitano LA, Lo JC, Gotway MB, Mulligan K, Barbour JD, Schmidt D, Grant RM, Halvorsen RA, Schambelan M, McCune JM. 2002. Increased thymic mass and circulating naive CD4 T cells in HIV-1-infected adults treated with growth hormone. AIDS 16:1103-1111.
29. Napolitano LA, Schmidt D, Gotway MB, Ameli N, Filbert EL, Ng MM, Clor JL, Epling L, Sinclair E, Baum PD, Li K, Killian ML, Bacchetti P, McCune JM. 2008. Growth hormone enhances thymic function in HIV-1-infected adults. J Clin Invest 118:1085-1098.
30. Pires A, Pido-Lopez J, Moyle G, Gazzard B, Gotch F, Imami N. 2004. Enhanced T-cell maturation, differentiation and function in HIV-1-infected individuals after growth hormone and highly active antiretroviral therapy. Antivir Ther 9:67-75.
31. Rietschel P, Hadigan C, Corcoran C, Stanley T, Neubauer G, Gertner J, Grinspoon S. 2001. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metab 86:504-510.
32. Yerly S, Chamot E, Hirschel B, Perrin LH. 1992. Quantitation of human immunodeficiency virus provirus and circulating virus: Relationship with immunologic parameters. J Infect Dis 166:269-276.